hVIVO plc Result of General Meeting (0115J)
16 December 2015 - 1:00AM
UK Regulatory
TIDMHVO
RNS Number : 0115J
hVIVO plc
15 December 2015
For immediate release 14.00: 15 December 2015
HVIVO PLC
("hVIVO" or the "Company")
RESULT OF GENERAL MEETING
hVIVO plc (AIM: HVO), the pioneer of human challenge models of
disease, is pleased to announce that the resolutions put to
shareholders at today's General Meeting, in connection with the
Placing announced by the Company on 26 November 2015, were duly
passed.
Following the passing of the resolutions at the General Meeting,
9,111,111 new Ordinary Shares have been allotted to investors,
conditional upon the admission of such Ordinary Shares to trading
on AIM. It is expected that settlement will occur, admission to
trading on AIM will become effective and dealings will commence in
respect of the 9,111,111 new Ordinary Shares at 8.00am on 16
December 2015.
Following admission of the 9,111,111 new Ordinary Shares to
trading on AIM, the total number of Ordinary Shares with voting
rights in issue will be 78,052,784 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Upon admission, the new Ordinary Shares will be issued, credited
as fully paid and will rank pari passu in all respects with the
existing Ordinary Shares of the Company.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public
Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO is a life sciences company pioneering a technology
platform of human disease models to accelerate drug discovery and
development in respiratory and infectious diseases.
Through its illumination of the entire disease life cycle from
healthy to sick and back to health, the hVIVO platform captures
disease in motion and promotes rational selection of drug targets
and biomarkers in respiratory and infectious diseases, such as flu
and colds. It brings together a revolutionary set of capabilities
in product validation testing and the mining of biological
insights, in order to tackle the long timeline, significant costs
and high risks to market facing drug development and diagnostic
organisations today.
A market leader in human disease models and challenge studies,
hVIVO has commercialised four disease models, successfully enrolled
over 2,000 subjects and conducted over 40 product validation
studies for a wide range of industry, government and academia
clients and collaborators.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMLLFSRFSLSLIE
(END) Dow Jones Newswires
December 15, 2015 09:00 ET (14:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024